Powered by 
Technavio
Mirati Therapeutics | Data-Driven Analysis and Industry Review
Published: August 20, 2024Mirati Therapeutics is a biotechnology company focused on discovering, developing, and commercializing targeted therapies for genetically-defined cancers. The company's approach is rooted in the scientific understanding of the genetic and molecular complexities of cancer, with a focus on developing novel therapies that address specific genetic mutations. Mirati's lead product candidate, MRTX849, is a potent and selective KRASG12C inhibitor currently in clinical development for the treatment of non-small cell lung cancer and colorectal cancer. The company's pipeline also includes other programs targeting RAS, MET, and other genetic drivers of cancer. Mirati is headquartered in Morrisville, North Carolina.'
1. Mirati Therapeutics is a clinical-stage biotech company focused on developing targeted therapies for genetically-defined cancers, using their proprietary technology platform, Thera-Targeting Technology, to identify and validate targets.
2. The company's pipeline includes multiple programs in development for various types of cancer, such as KRAS G12C inhibitors, MET inhibitors, and other targeted therapies.
3. Mirati Therapeutics has strategic collaborations with major pharmaceutical companies, including Roche and Merck, to expand its research and development capabilities and bring its therapies to market.
4. The company's lead product, Adagrasib (MRTX849), is a KRAS G12C inhibitor that has shown promising results in clinical trials for the treatment of non-small cell lung cancer and colorectal cancer.
5. Mirati Therapeutics has a strong intellectual property portfolio, with over 50 issued patents and over 100 pending applications, providing a competitive advantage in the development of its targeted therapies.
1. Mirati Therapeutics is a biotechnology company specializing in the discovery, development, and commercialization of targeted therapies for genetically-defined cancers.
2. They employ a unique approach to cancer treatment by utilizing their proprietary understanding of genetic and molecular drivers of cancer to design and develop small molecule inhibitors.
3. Mirati Therapeutics' pipeline includes several investigational therapies in various stages of clinical development, targeting specific genetic mutations in cancer.
4. The company's lead program, MRTX849, is a KRASG12C inhibitor currently in Phase 3 clinical trials for the treatment of non-small cell lung cancer and colorectal cancer.
5. Mirati Therapeutics also collaborates with other pharmaceutical and biotech companies, academic institutions, and patient advocacy groups to expand their research capabilities and accelerate the development of their therapies.
Browse Our Research Portfolio In Mirati Therapeutics Markets
Health Care
Biotechnology and Life Sciences
Pharmaceuticals
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
